Share this post on:

Product Name :
MCC-950

Search keywords :
MCC950

drugId :
null

Target Vo:
NACHT, LRR and PYD domains-containing protein 3

Target Vo Short Name :
NLRP3

Moa_Name:
NACHT, LRR and PYD domains-containing protein 3 inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
The University Of Queensland

Active Company_Name :
The University Of Queensland

Active Indication_Name:
Parkinson Disease

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Preclinical

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Integrin beta 1 Antibody
DLAT Antibody (YA912)
Phospho-AMPK alpha 1 (Ser496) Antibody (YA226): Phospho-AMPK alpha 1 (Ser496) Antibody (YA226) is a non-conjugated and Rabbit origined monoclonal antibody about 64 kDa, targeting to Phospho-AMPK alpha 1 (S496). It can be used for WB,ICC/IF,IP assays with tag free, in the background of Human.

Share this post on:

Author: Interleukin Related